Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. Despite this curative …

Despite progress in the therapeutic management of patients with squamous cell carcinoma
of the head and neck (SCCHN), the mortality rate of patients presenting with advanced …

Head and neck squamous cell carcinoma (HNSCC) is a common malignancy with high rates
of mortality and morbidity. Beginning with cetuximab, investigators continue to optimize …

Recently, new targets have been identified in head and neck squamous cell carcinomas
(HNSCC) as playing key roles in tumour proliferation and metastases. The first target that …

The development of epidermal growth factor receptor (EGFR) inhibitors was greeted with
tremendous enthusiasm in the therapy of squamous cell carcinoma of the head and neck …

Introduction: Despite improvements in treatment, survival rates of head and neck squamous
cell carcinoma (HNSCC) are stagnant. The existing chemotherapeutic agents are non …

In this review, key aspects of epidermal growth factor receptor (EGFR) biology and the fruitful
translation of these fundamental findings into recent treatment advances in head and neck …

Introduction: Subsequent to the 2006 FDA approval of cetuximab, a variety of molecular
targeting agents have been evaluated in head and neck squamous cell carcinoma …

Squamous cell head and neck cancer (SCCHN) is the seventh most common cause of
cancer death worldwide and its incidence is rising rapidly in developing countries. Despite …

Objectives Despite dramatic developments in drugs established for other malignancies,
historically there have been few novel systemic agents available for the management of …